Breast Cancer in the United States: A Cross-Sectional Overview

Table 3

5-year and 10-year overall survival (OS) of patients diagnosed between 2004 and 2016.

Variable	5-year OS		10-year OS
	Probability	95% CI	Probability	95% CI
By stage
0	94%	94-94%	83%	83-84%
I	90%	90-90%	75%	75-76%
II	83%	83-83%	67%	67-67%
III	66%	66-66%	47%	47-47%
IV	23%	23-23%	9.20%	8.9-9.5%
By molecular subtype
HR+, HER2-	84%	84-84%	—	—
HR+, HER2+	83%	83-84%	—	—
HR-, HER2-	71%	71-71%	—	—
HR+, HER2+	77%	76-77%	—	—
By histologic subtype
Ductal carcinoma	84%	84-84%	70%	70-70%
Lobular carcinoma	84%	84-85%	68%	68-69%
Adenocarcinoma of mixed subtypes	81%	79-84%	65%	61-69%
Metaplastic carcinoma	63%	62-64%	50%	48-51%
Rare breast carcinomas	92%	91-92%	80%	79-81%
Inflammatory invasive carcinoma	39%	38-40%	25%	24-26%
Other carcinomas	84%	84-84%	71%	70-71%
Epithelial-myoepithelial	56%	55-57%	44%	43-45%
Intraductal papillary	90%	89-90%	78%	77-79%
Papillary	83%	82-84%	63%	62-65%
Fibroepithelial	83%	82-85%	74%	71-76%
Mesenchymal	47%	44-50%	35%	31-38%
Tumors of the nipple	81%	79-83%	65%	61-68%
Carcinoid tumor	60%	39-92%	40%	16-99%
Malignant lymphoma	65%	41-100%	—	—
By race
White	84%	84-84%	69%	69-70%
Black	78%	78-78%	63%	63-63%
Other, including Asian and Pacific Islander	90%	90-90%	81%	80-81%
By facility type
Community cancer program	80%	80-80%	63%	63-64%
Comprehensive community cancer program	83%	83-83%	68%	68-68%
Academic cancer program	85%	85-85%	72%	72-72%
Integrated cancer program	84%	84-84%	69%	69-70%

10-year OS data is not available by receptor subtype, as HER2 status is not documented in NCDB prior to 2009. 10-year OS data also not available for patients with malignant lymphoma of the breast due to the year of diagnosis within the last years.